Keep Current with the Latest in Cell Biology Research

Tissue CD14+CD8+ T Cells Reprogrammed by Myeloid Cells and Modulated by LPS

[Nature] Researchers showed that a variable proportion of CD8+ T cells compartmentalized in the human liver co-stained for CD14 and other prototypic myeloid membrane proteins and were enriched in close proximity to CD14high myeloid cells in hepatic zone 2.

Intrathymic Dendritic Cell-Biased Precursors Promote Human T Cell Lineage Specification through IRF8-Driven Transmembrane TNF

[Nature Immunology] In vitro recapitulation of TNF receptor 2 (TNFR2) signaling, by providing low-density membrane-bound precursor form of the cytokine TNF or a selective TNFR2 agonist, enhanced the generation of human T cell precursors.

CD200+ Cytotoxic T Lymphocytes in the Tumor Microenvironment Are Crucial for Efficacious Anti–PD-1/PD-L1 Therapy

[Science Translational Medicine] Scientists found an increase in tumor-infiltrating CD200+ cytotoxic T lymphocytes upon PD-1/PD-L1 blockade, with higher proportions of CD200+ T cells positively related to a favorable clinical outcome to anti–PD-1/PD-L1 therapy in three independent cohorts of patients with cancer.

Expansion of Interferon Inducible Gene Pool via USP18 Inhibition Promotes Cancer Cell Pyroptosis

[Nature Communications] Lower USP18 expression correlated with better survival across human selected cancer types and delayed cancer progression in mouse models.

Persistent Mutation Burden Drives Sustained Anti-Tumor Immune Responses

[Nature Medicine] Investigators evaluated mutations in regions of the genome that were unlikely to undergo loss in a pan-cancer analysis across 31 tumor types and eight immunotherapy-treated cohorts of patients with non-small-cell lung cancer, melanoma, mesothelioma, and head and neck cancer.

Combined PD-1, BRAF and MEK Inhibition in BRAFV600E Colorectal Cancer: A Phase II Trial

[Nature Medicine] The authors performed a proof-of-concept single-arm phase II clinical trial of combined PD-1, BRAF and MEK inhibition with sparatlizumab, dabrafenib, and trametinib in 37 patients with BRAFV600E colorectal cancer.

Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy

[JAMA Oncology] This cohort study was performed in approximately 280 predominantly community-based US cancer clinics and included patients aged 18 years or older who had stage IIIB, IIIC, or IV non-small cell lung cancer.

Multi-Antigen Spherical Nucleic Acid Cancer Vaccines

[Nature Biomedical Engineering] The authors used spherical nucleic acid nanoparticles to investigate how the spatial distribution and placement of two antigen classes affected antigen processing, cytokine production, and the induction of memory.

Multiplex Immune Profiling Reveals the Role of Serum Immune Proteomics in Predicting Response to Preoperative Chemotherapy of Gastric Cancer

[Cell Reports Medicine] The authors collected serum samples from patients with gastric adenocarcinoma before, on, and after preoperative chemotherapy and studied their immune proteomics using an antibody-based proteomics panel.

CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy

[CLINICAL CANCER RESEARCH] Immune cells from tumor and peripheral blood were isolated from 42 patients with renal cell carcinoma and 5 patients with ovarian cancer. Researchers performed multicolor flow cytometry and RNA-sequencing to characterize the phenotypes and heterogeneity of intratumoral Tregs.

Targeted Modulation of Immune Cells and Tissues Using Engineered Biomaterials

[Nature Reviews Bioengineering] Scientists review recent advances in biomaterials-based strategies, focusing on targeting of lymphoid tissues, circulating leukocytes, tissue-resident immune cells and immune cells at disease sites.

Targeting Protein Phosphatases in Cancer Immunotherapy and Autoimmune Disorders

[Nature Reviews Drug Discovery] The authors discuss recent progress in phosphatase drug discovery, with emphasis on the development of selective modulators that exhibit biological activity. The roles and regulation of protein phosphatases in immune cells and their potential as powerful targets for immuno-oncology and autoimmunity indications are assessed.

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.